Supplementary Fig. S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma2024
2Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma2024
3Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma2024
4Supplementary Fig. S6 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma2024
5Supplementary Fig. S6 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma2024